Evidence map›Paper›PMID 39355029›Full record

ReviewFrontiers in nuclear medicine2023

The application of radionuclide therapy for breast cancer.

Anna Musket, Sandra Davern, Brianna M Elam, Philip R Musich, Jonathan P Moorman, Yong Jiang

Abstract readReview
In one paragraph

Review in Frontiers in nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Rhenium-186-labeledRSC advances · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna MusketDepartment of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.
Sandra DavernOak Ridge National Laboratory, Oak Ridge, TN, United States.
Brianna M ElamDepartment of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.
Philip R MusichDepartment of Biomedical Science, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.
Jonathan P MoormanDepartment of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.
Yong JiangDepartment of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radionuclide-mediated diagnosis and therapy have emerged as effective and low-risk approaches to treating breast cancer. Compared to traditional anatomic imaging techniques, diagnostic radionuclide-based molecular imaging systems exhibit much greater sensitivity and ability to precisely illustrate the biodistribution and metabolic processes from a functional perspective in breast cancer; this transitions diagnosis from an invasive visualization to a noninvasive visualization, potentially ensuring earlier diagnosis and on-time treatment. Radionuclide therapy is a newly developed modality for the treatment of breast cancer in which radionuclides are delivered to tumors and/or tumor-associated targets either directly or using delivery vehicles. Radionuclide therapy has been proven to be eminently effective and to exhibit low toxicity when eliminating both primary tumors and metastases and even undetected tumors. In addition, the specific interaction between the surface modules of the delivery vehicles and the targets on the surface of tumor cells enables radionuclide targeting therapy, and this represents an exceptional potential for this treatment in breast cancer. This article reviews the development of radionuclide molecular imaging techniques that are currently employed for early breast cancer diagnosis and both the progress and challenges of radionuclide therapy employed in breast cancer treatment.

Indexed as

breast cancerearly diagnosisradionuclidetherapytumor

Identifiers

PMID39355029
PMCPMC11440853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.